Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 343

1.

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis.

Akdemir G, Markusse IM, Bergstra SA, Goekoop RJ, Molenaar ET, van Groenendael JHLM, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF.

RMD Open. 2018 May 20;4(1):e000649. doi: 10.1136/rmdopen-2018-000649. eCollection 2018.

2.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

3.

An Economic Evaluation of Stopping versus Continuing TNF-Inhibitor Treatment in Rheumatoid Arthritis Patients in Remission or Low Disease Activity: results from the POET randomized trial.

Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2018 May 9. doi: 10.1002/art.40546. [Epub ahead of print]

PMID:
29745059
4.

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.

Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5. Epub 2018 Apr 6.

PMID:
29631782
5.

An unfavorable body composition is common in early arthritis patients: A case control study.

Turk SA, van Schaardenburg D, Boers M, de Boer S, Fokker C, Lems WF, Nurmohamed MT.

PLoS One. 2018 Mar 22;13(3):e0193377. doi: 10.1371/journal.pone.0193377. eCollection 2018.

6.

TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years.

Loef M, Kroon FPB, Bergstra SA, van der Pol JA, Lems WF, Kerstens PJSM, Allaart CF, Kloppenburg M.

Rheumatology (Oxford). 2018 Feb 19. doi: 10.1093/rheumatology/key016. [Epub ahead of print]

PMID:
29471377
7.

Clinically relevant discrepancies between different rheumatoid factor assays.

Falkenburg WJJ, von Richthofen HJ, Koers J, Weykamp C, Schreurs MWJ, Bakker-Jonges LE, Haagen IA, Lems WF, Hamann D, van Schaardenburg D, Rispens T.

Clin Chem Lab Med. 2018 Feb 10. pii: /j/cclm.ahead-of-print/cclm-2017-0988/cclm-2017-0988.xml. doi: 10.1515/cclm-2017-0988. [Epub ahead of print]

PMID:
29427550
8.

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.

Hartman L, Rasch LA, Klausch T, Bijlsma HWJ, Christensen R, Smulders YM, Ralston SH, Buttgereit F, Cutolo M, Da Silva JAP, Opris D, Rovenský J, Szamosi S, Middelink LM, Lems WF, Boers M.

Trials. 2018 Jan 25;19(1):67. doi: 10.1186/s13063-017-2396-3.

9.

Glucocorticoids, Inflammation and Bone.

Güler-Yüksel M, Hoes JN, Bultink IEM, Lems WF.

Calcif Tissue Int. 2018 May;102(5):592-606. doi: 10.1007/s00223-017-0335-7. Epub 2018 Jan 8. Review.

PMID:
29313071
10.

Bisphosphonates: a therapeutic option for knee osteoarthritis?

Lems WF.

Ann Rheum Dis. 2017 Dec 13. pii: annrheumdis-2017-212364. doi: 10.1136/annrheumdis-2017-212364. [Epub ahead of print] No abstract available.

PMID:
29237617
11.

Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs.

Lems WF, Raterman HG.

Ther Adv Musculoskelet Dis. 2017 Dec;9(12):299-316. doi: 10.1177/1759720X17732562. Epub 2017 Oct 27. Review.

12.

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Ter Wee MM, Coupé VM, den Uyl D, Blomjous BS, Kooijmans E, Kerstens PJ, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Boers M, Lems WF.

RMD Open. 2017 Oct 25;3(2):e000502. doi: 10.1136/rmdopen-2017-000502. eCollection 2017.

13.

What have we learned from BeSt?

Allaart CF, Markusse IM, Lems WF.

Clin Immunol. 2018 Jan;186:74-78. doi: 10.1016/j.clim.2017.09.017. Epub 2017 Sep 18.

14.

Inflammatory diseases and bone fragility.

Briot K, Geusens P, Em Bultink I, Lems WF, Roux C.

Osteoporos Int. 2017 Dec;28(12):3301-3314. doi: 10.1007/s00198-017-4189-7. Epub 2017 Sep 15. Review.

PMID:
28916915
15.

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Rheumatology (Oxford). 2017 Sep 1;56(9):1586-1596. doi: 10.1093/rheumatology/kex223.

PMID:
28859326
16.

Analgesic use in patients with knee and/or hip osteoarthritis referred to an outpatient center: a cross-sectional study within the Amsterdam Osteoarthritis Cohort.

Knoop J, van Tunen J, van der Esch M, Roorda LD, Dekker J, van der Leeden M, Lems WF.

Rheumatol Int. 2017 Oct;37(10):1747-1755. doi: 10.1007/s00296-017-3785-3. Epub 2017 Aug 18.

PMID:
28821939
17.

Effect of implementation of guidelines on assessment and diagnosis of vertebral fractures in patients older than 50 years with a recent non-vertebral fracture.

van der Velde RY, Bours SPG, Wyers CE, Lems WF, Geusens PPMM, van den Bergh JPW.

Osteoporos Int. 2017 Oct;28(10):3017-3022. doi: 10.1007/s00198-017-4147-4. Epub 2017 Jul 26.

18.

Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.

Ibáñez Vodnizza SE, Nurmohamed MT, Visman IM, van Denderen JC, Lems WF, Jaime F, van der Horst-Bruinsma IE.

J Rheumatol. 2017 Sep;44(9):1355-1361. doi: 10.3899/jrheum.170094. Epub 2017 Jul 15.

PMID:
28711878
19.

Nonlinear relationship between isokinetic muscle strength and activity limitations in patients with knee osteoarthritis: Results of the Amsterdam-Osteoarthritis cohort.

Edelaar LM, van Dieën JH, van der Esch M, Roorda LD, Dekker J, Lems WF, van der Leeden M.

J Rehabil Med. 2017 Jul 7;49(7):598-605. doi: 10.2340/16501977-2252.

20.

Muscle wasting in male TNF-α blocker naïve ankylosing spondylitis patients: a comparison of gender differences in body composition.

Ibáñez Vodnizza S, Visman IM, van Denderen C, Lems WF, Jaime F, Nurmohamed MT, van der Horst-Bruinsma IE.

Rheumatology (Oxford). 2017 Sep 1;56(9):1566-1572. doi: 10.1093/rheumatology/kex187.

PMID:
28605535

Supplemental Content

Support Center